Multiple sclerosis
Department of Pharmacology NRI College of Pharmacy Pothavarappadu Agiripalli India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2024, 26(02), 038–043.
Article DOI: 10.30574/gscbps.2024.26.2.0378
Publication history:
Received on 02 August 2023; revised on 12 September 2023; accepted on 15 September 2023
Abstract:
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesions in the gray and white matter and to diffuse neurodegeneration in the entire brain. In this review, the spectrum of MS lesion s and their relation to the inflammatory process is described. Pathology suggests that inflammation drives tissue injury at all stages of the disease. Focal inflammatory infiltrates in the meninges and the perivascular spaces appear to produce soluble factors, which induce demyelination or neuro- degeneration either directly or indirectly through microglia activation. The nature of these soluble factors, which are responsible for demyelinating activity in sera and cerebrospinal fluid of the patients, is currently undefined. Demyelination and neurodegeneration are finally accomplished by oxidative injury and mitochondrial damage leading to a state of “virtual hypoxia.”
Keywords:
Demyelination; Virtual hypoxia; Neurodegeneration; Microglia activation; Spasticity
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
